Stay updated with breaking news from Aging Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two recently approved treatments offer newfound hope for patients in the early stages of Alzheimer's disease, but most people who could benefit will likely be deemed ineligible, a new study finds.
Only a small percentage of people with early AD may be eligible to receive treatment, mostly due to chronic health conditions and brain scan abnormalities common in older adults.
If the FDA grants Lecanemab full approval, medical experts say Medicaid and Medicare will likely cover it
In an eight-year study of more than 600 community-dwelling older adults, Johns Hopkins Medicine researchers say they have further linked levels of cell-free DNA (DNA fragments resulting from cell death) circulating in the blood to chronic inflammation and frailty.
Sessions in June and July